April to May 2025

EU-funded public-private partnership formed to develop Vivaldi's DeltaFLU vaccine candidate, announced in Cnossen 2025

US HHS funding announced to develop NIAID's BPL-1357, as noted in STAT and KFF Health News. Results of NIAID's BPL-1357 Phase 1 trial NCT05027932 posted on Clinicaltrials.gov

Analysis of broadly protective immune responses in newborn NHPs to NIAID’s HA-stem ferritin nanoparticle vaccine (H1ssF+AddaVax) in Crofts 2025

Results of Moderna's mRNA-1010 Phase 3 trials NCT05415462 and NCT05566639 published in Kandinov 2025

Analysis of B cell responses against broadly protective epitopes of the HA stalk domain following chimeric HA vaccination, published in Guthmiller 2025

New Phase 1 trial NCT06863142 of NIAID’s FluMos-v2 mosaic hexavalent nanoparticle vaccine with and without ALFQ adjuvant